Dynogen’s GI, GU Products To Benefit From $50M Round (BioWorld Today)

News | 04. 20. 2004

Dynogen Pharmaceuticals

In its largest financing to date, Dynogen Pharmaceuticals Inc. secured $50 million in a Series B round, enabling it to build its pipeline and advance its two clinical com- pounds.